Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation

[Guest guest]

Transplantation. 2004 Aug 27;78(4):580-3.

Hepatitis C virus infection with hepatocellular carcinoma: not a

controversial indication for liver transplantation.

-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas

HE.

Division of Transplantation Medicine, Department of Internal Medicine, Mayo

Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85254, USA.

Luna.@...

BACKGROUND: The association of hepatocellular carcinoma (HCC) and chronic

hepatitis C virus (HCV) infection has been identified as a potential

contraindication for orthotopic liver transplantation (LT) because of lower

survival rate compared with other indications. AIM: Evaluate the outcome of

patients with and without HCC and cirrhosis with and without chronic HCV

infection undergoing transplantation. Determine the postLT HCC recurrence

rate and frequency of de novo postLT HCC. PATIENTS AND METHODS: United

Network for Organ Sharing (UNOS) data was collected from January 1998 to

December 2002. Cohort included 17,968 patients (11,552 M; 6,416 F) with a

mean age of 51 (18-87) years. Four groups were established: HCV (n = 7,079),

HCC (n = 611), HCV+HCC (n = 1,078), and no HCV/no HCC (n = 9,200). The

overall survival rate was calculated at 24 and 48 months postLT. RESULTS:

Patient survival at 24 months and 48 months was 84% and 75% for HCV, 84% and

68% for HCC, 78% and 72% for HCV+HCC, and 85% and 80% for no HCV/no HCC,

respectively. Survival at 48 months among the two groups was not

significantly different (NS). Further analysis of these groups revealed a

statistically significant advantage in survival at 48 months postLT for the

no HCV/no HCC group when compared with the HCV group.(P < 0.05) The reported

rate of postLT HCC recurrence and de novo postLT HCC was 3.3% and 0.05%,

respectively. CONCLUSION: In this large cohort of U.S. patients, HCC does

not have an impact on the survival of LT patients infected with HCV.

PMID: 15446318 [PubMed - in process]

[Guest guest]

Transplantation. 2004 Aug 27;78(4):580-3.

Hepatitis C virus infection with hepatocellular carcinoma: not a

controversial indication for liver transplantation.

-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas

HE.

Division of Transplantation Medicine, Department of Internal Medicine, Mayo

Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85254, USA.

Luna.@...

BACKGROUND: The association of hepatocellular carcinoma (HCC) and chronic

hepatitis C virus (HCV) infection has been identified as a potential

contraindication for orthotopic liver transplantation (LT) because of lower

survival rate compared with other indications. AIM: Evaluate the outcome of

patients with and without HCC and cirrhosis with and without chronic HCV

infection undergoing transplantation. Determine the postLT HCC recurrence

rate and frequency of de novo postLT HCC. PATIENTS AND METHODS: United

Network for Organ Sharing (UNOS) data was collected from January 1998 to

December 2002. Cohort included 17,968 patients (11,552 M; 6,416 F) with a

mean age of 51 (18-87) years. Four groups were established: HCV (n = 7,079),

HCC (n = 611), HCV+HCC (n = 1,078), and no HCV/no HCC (n = 9,200). The

overall survival rate was calculated at 24 and 48 months postLT. RESULTS:

Patient survival at 24 months and 48 months was 84% and 75% for HCV, 84% and

68% for HCC, 78% and 72% for HCV+HCC, and 85% and 80% for no HCV/no HCC,

respectively. Survival at 48 months among the two groups was not

significantly different (NS). Further analysis of these groups revealed a

statistically significant advantage in survival at 48 months postLT for the

no HCV/no HCC group when compared with the HCV group.(P < 0.05) The reported

rate of postLT HCC recurrence and de novo postLT HCC was 3.3% and 0.05%,

respectively. CONCLUSION: In this large cohort of U.S. patients, HCC does

not have an impact on the survival of LT patients infected with HCV.

PMID: 15446318 [PubMed - in process]

[Guest guest]

Transplantation. 2004 Aug 27;78(4):580-3.

Hepatitis C virus infection with hepatocellular carcinoma: not a

controversial indication for liver transplantation.

-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas

HE.

Division of Transplantation Medicine, Department of Internal Medicine, Mayo

Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85254, USA.

Luna.@...

BACKGROUND: The association of hepatocellular carcinoma (HCC) and chronic

hepatitis C virus (HCV) infection has been identified as a potential

contraindication for orthotopic liver transplantation (LT) because of lower

survival rate compared with other indications. AIM: Evaluate the outcome of

patients with and without HCC and cirrhosis with and without chronic HCV

infection undergoing transplantation. Determine the postLT HCC recurrence

rate and frequency of de novo postLT HCC. PATIENTS AND METHODS: United

Network for Organ Sharing (UNOS) data was collected from January 1998 to

December 2002. Cohort included 17,968 patients (11,552 M; 6,416 F) with a

mean age of 51 (18-87) years. Four groups were established: HCV (n = 7,079),

HCC (n = 611), HCV+HCC (n = 1,078), and no HCV/no HCC (n = 9,200). The

overall survival rate was calculated at 24 and 48 months postLT. RESULTS:

Patient survival at 24 months and 48 months was 84% and 75% for HCV, 84% and

68% for HCC, 78% and 72% for HCV+HCC, and 85% and 80% for no HCV/no HCC,

respectively. Survival at 48 months among the two groups was not

significantly different (NS). Further analysis of these groups revealed a

statistically significant advantage in survival at 48 months postLT for the

no HCV/no HCC group when compared with the HCV group.(P < 0.05) The reported

rate of postLT HCC recurrence and de novo postLT HCC was 3.3% and 0.05%,

respectively. CONCLUSION: In this large cohort of U.S. patients, HCC does

not have an impact on the survival of LT patients infected with HCV.

PMID: 15446318 [PubMed - in process]

[Guest guest]

Transplantation. 2004 Aug 27;78(4):580-3.

Hepatitis C virus infection with hepatocellular carcinoma: not a

controversial indication for liver transplantation.

-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas

HE.

Division of Transplantation Medicine, Department of Internal Medicine, Mayo

Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85254, USA.

Luna.@...

BACKGROUND: The association of hepatocellular carcinoma (HCC) and chronic

hepatitis C virus (HCV) infection has been identified as a potential

contraindication for orthotopic liver transplantation (LT) because of lower

survival rate compared with other indications. AIM: Evaluate the outcome of

patients with and without HCC and cirrhosis with and without chronic HCV

infection undergoing transplantation. Determine the postLT HCC recurrence

rate and frequency of de novo postLT HCC. PATIENTS AND METHODS: United

Network for Organ Sharing (UNOS) data was collected from January 1998 to

December 2002. Cohort included 17,968 patients (11,552 M; 6,416 F) with a

mean age of 51 (18-87) years. Four groups were established: HCV (n = 7,079),

HCC (n = 611), HCV+HCC (n = 1,078), and no HCV/no HCC (n = 9,200). The

overall survival rate was calculated at 24 and 48 months postLT. RESULTS:

Patient survival at 24 months and 48 months was 84% and 75% for HCV, 84% and

68% for HCC, 78% and 72% for HCV+HCC, and 85% and 80% for no HCV/no HCC,

respectively. Survival at 48 months among the two groups was not

significantly different (NS). Further analysis of these groups revealed a

statistically significant advantage in survival at 48 months postLT for the

no HCV/no HCC group when compared with the HCV group.(P < 0.05) The reported

rate of postLT HCC recurrence and de novo postLT HCC was 3.3% and 0.05%,

respectively. CONCLUSION: In this large cohort of U.S. patients, HCC does

not have an impact on the survival of LT patients infected with HCV.

PMID: 15446318 [PubMed - in process]